+

PE20061372A1 - Composicion farmaceutica que contiene un vector adenovirus - Google Patents

Composicion farmaceutica que contiene un vector adenovirus

Info

Publication number
PE20061372A1
PE20061372A1 PE2006000493A PE2006000493A PE20061372A1 PE 20061372 A1 PE20061372 A1 PE 20061372A1 PE 2006000493 A PE2006000493 A PE 2006000493A PE 2006000493 A PE2006000493 A PE 2006000493A PE 20061372 A1 PE20061372 A1 PE 20061372A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
adenovirus vector
composition containing
nef
hiv
Prior art date
Application number
PE2006000493A
Other languages
English (en)
Inventor
Peter Franz Ertl
John Philip Tite
Wely Catherine Ann Van
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061372(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20061372A1 publication Critical patent/PE20061372A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN VECTOR ADENOVIRUS SELECCIONADO DE PAN 6 O PAN7 CARACTERIZADO POR A) TENER DELECIONES EN LAS REGIONES E1 Y E3; Y B) CODIFICAR AL MENOS LOS ANTIGENOS DE VIH RT, Nef Y Gag O DERIVADOS INMUNOGENICOS O FRAGMENTOS INMUNOGENOS DE LOS MISMOS, DISPUESTOS DE FORMA QUE SE TRANSCRIBEN EN EL ORDEN Gag, RT, Nef. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION FARMACEUTICA ES UTIL EN EL TRATAMIENTO DE VIH-1
PE2006000493A 2005-05-12 2006-05-10 Composicion farmaceutica que contiene un vector adenovirus PE20061372A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68038905P 2005-05-12 2005-05-12

Publications (1)

Publication Number Publication Date
PE20061372A1 true PE20061372A1 (es) 2007-01-16

Family

ID=36954770

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000493A PE20061372A1 (es) 2005-05-12 2006-05-10 Composicion farmaceutica que contiene un vector adenovirus

Country Status (20)

Country Link
US (1) US20090208515A1 (es)
EP (1) EP1880012B1 (es)
JP (2) JP5175178B2 (es)
KR (1) KR101451620B1 (es)
CN (2) CN101384722A (es)
AR (1) AR053275A1 (es)
AU (1) AU2006245920A1 (es)
BR (1) BRPI0608798A2 (es)
CA (1) CA2608316A1 (es)
EA (1) EA200702190A1 (es)
ES (1) ES2546330T3 (es)
IL (1) IL186828A (es)
MA (1) MA29458B1 (es)
MX (1) MX2007014038A (es)
NO (1) NO20075648L (es)
PE (1) PE20061372A1 (es)
SG (1) SG182173A1 (es)
TW (1) TW200716750A (es)
WO (1) WO2006120034A1 (es)
ZA (1) ZA200709518B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247472B2 (en) 2001-11-21 2007-07-24 The Trustees Of The University Of Pennsylavania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
EP2998316B1 (en) * 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Novel method and compositions
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
BRPI0822651A2 (pt) 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília b de adenovírus sadv-28, -27, 29, -32, -33 e -35 de símio e seus usos
PT2220241T (pt) * 2007-11-28 2016-12-26 Univ Pennsylvania Adenovírus compreendendo uma proteína hexão da cápside do adenovírus e símio sadv-39 e suas utilizações
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
KR101814857B1 (ko) 2011-04-06 2018-01-04 바이오백심 리미티드 인간에서의 hiv 질환의 예방 및/또는 치료를 위한 제약 조성물
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5770952B2 (ja) 2012-03-12 2015-08-26 クルセル ホランド ベー ヴェー 改変末端を有する組換えアデノウイルスのバッチ
CA2873509A1 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
CA2906053C (en) * 2013-03-14 2023-08-15 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
DK3271729T3 (da) 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv Analyser til rekombinante ekspressionssystemer
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CA2988481A1 (en) * 2015-06-12 2016-12-15 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2017011336A1 (en) 2015-07-10 2017-01-19 E.&J. Gallo Winery System and method for dispensing a beverage
WO2017194655A1 (en) 2016-05-12 2017-11-16 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
CN109804075A (zh) 2016-08-01 2019-05-24 威斯塔解剖学和生物学研究所 用于疫苗应用的复制缺陷型腺病毒载体的组合物和方法
JP6721797B2 (ja) 2017-02-09 2020-07-15 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 異種遺伝子発現のための強力で短いプロモーター

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
WO2002022080A2 (en) * 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
HU228327B1 (en) * 2001-06-22 2013-03-28 Wistar Inst Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
IL160809A0 (en) * 2001-09-20 2004-08-31 Glaxo Group Ltd HIV-gag CODON-OPTIMISED DNA VACCINES
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
EP1682666B1 (en) * 2003-09-24 2008-12-31 Oxxon Therapeutics Limited HIV Pharmaceutical vaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
JP2008539746A (ja) 2008-11-20
EP1880012B1 (en) 2015-07-08
WO2006120034A1 (en) 2006-11-16
MX2007014038A (es) 2008-02-11
CN101384722A (zh) 2009-03-11
ZA200709518B (en) 2014-01-29
WO2006120034A8 (en) 2007-11-15
CN103088060A (zh) 2013-05-08
EA200702190A1 (ru) 2008-04-28
US20090208515A1 (en) 2009-08-20
IL186828A0 (en) 2008-02-09
KR20080021659A (ko) 2008-03-07
KR101451620B1 (ko) 2014-10-21
CA2608316A1 (en) 2006-11-16
MA29458B1 (fr) 2008-05-02
ES2546330T3 (es) 2015-09-22
JP2013046613A (ja) 2013-03-07
JP5175178B2 (ja) 2013-04-03
AR053275A1 (es) 2007-04-25
EP1880012A1 (en) 2008-01-23
NO20075648L (no) 2008-02-07
IL186828A (en) 2015-06-30
SG182173A1 (en) 2012-07-30
AU2006245920A1 (en) 2006-11-16
BRPI0608798A2 (pt) 2011-03-15
TW200716750A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
PE20061372A1 (es) Composicion farmaceutica que contiene un vector adenovirus
SG155206A1 (en) Vaccine for prevention and treatment of hiv-infection
MA32018B1 (fr) Vaccin
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
CL2004000270A1 (es) Compuestos derivados de pirazol, sus sales de adicion acidas,trastornos de vih y virus geneticamente relacionados. hidratos, solvatos; composiciones farmaceuticas; y su uso en el tramiento de trastornos del vih y virus geneticamente relacionados.
CL2012002744A1 (es) Compuesto inhibidor no nucleosídico de la transcriptasa inversa derivado de 3-(hidrocarbiloxi aromático y alifático opcionalmente sustituido)-1-[(5-oxo-4,5-dihidro-1h-1,2,4-triazol-3-il)metil])-piridin-2(ih)-ona; composición farmacéutica que lo comprende útil en la profilaxis y tratamiento de la infección por vih y sida.
CL2011002494A1 (es) Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih).
BRPI0506764A (pt) microemulsões para composições farmacêuticas
BR0212807A (pt) Processo para a preparação de formas de dosagem de dissolução rápida
DK1401826T3 (da) Pyrazolderivater som inhibitorer for HIV-revers transcriptase
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
CL2012002743A1 (es) Combinación que comprende maraviroc, un inhibidor de proteasa de vih-1 y un potenciador famacocinetico, uso en la preparacion de un medicamento util en el tratmiento de infeccion por vih.
DK1765337T3 (da) Kombination af tenofovir, ritonavir og TMC114
NI200700176A (es) Compuestos peptídicos
NO20073046L (no) Utvalgte benzofuranderivater
TW200518742A (en) Entry inhibitors
WO2010127272A3 (en) Hydroxyethylamino sulfonamide derivatives
BRPI0504117A (pt) epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
CR9859A (es) Inhibidores de la enzima integrasa de vih
DE602005023437D1 (de) Als inhibitor von retroviraler protease geeignete ritonavir-analoge verbindung, herstellung der ritonavir-analogen verbindung und pharmazeutische zusammenetzung für die ritonavir-analoge verbindung
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载